The question I hear most often from pharma access and market access leaders right now is some version of: "Are you using AI?" Anyone who’s made a career in pharma access recognizes a familiar pressure when something arrives in new packaging. Dowd: Pharma leaders are under pressure to incorporate AI into their programs and prove measurable impact. Dowd: In patient access specifically, where does accepting a probabilistic answer carry the most risk? Access leaders who anchor every AI conversation to those outcomes will make better decisions for their programs.